Valneva announces major COVID-19 vaccine partnership with UK government
UK government invests in Valneva's manufacturing facility and secures supply of 60 million doses of Valneva's inactivated COVID-19 vaccine VLA2001, with option for another 130 million doses.
MVM Summer 2020 Newsletter
Recent updates regarding MVM team, new investments, and portfolio.
MVM invests in Paragon 28
MVM co-led the Series B financing of Paragon 28, a leading orthopedic foot and ankle company.
Valneva confirms participation in UK government COVID-19 vaccine response program
Valneva has reached agreement in principle with the UK government to provide up to 100 million doses of its SARS-CoV-2 vaccine candidate.
MVM invests in MDxHealth SA
MVM closed a growth investment in MDxHealth SA, a company that markets tests that optimize the care of patients with prostate cancer.
MVM leads investment round in SkyCell
MVM led the growth investment round in SkyCell, a company that has developed patented temperature-control technology to transport vaccines and biotechnology drugs.